Document is current
Any future updates will be listed below
-
Authors
Grau-Rivera, Oriol
Navalpotro-Gomez, Irene
Sánchez-Benavides, Gonzalo
Suárez-Calvet, Marc
Milà-Alomà, Marta
Arenaza-Urquijo, Eider M.
Salvadó, Gemma
Sala-Vila, Aleix
Shekari, Mahnaz
González-de-Echávarri, José Maria
Minguillón, Carolina
Niñerola-Baizán, Aida
Perissinotti, Andrés
Simon, Maryline
Kollmorgen, Gwendlyn
Zetterberg, Henrik
Blennow, Kaj
Gispert, Juan Domingo
Molinuevo, José Luis
,
Beteta, Annabella
Cacciaglia, Raffaele
Cañas, Alba
Deulofeu, Carme
Cumplido, Irene
Dominguez, Ruth
Emilio, Maria
Falcon, Carles
Fuentes, Sherezade
Hernandez, Laura
Huesa, Gema
Huguet, Jordi
Fauria, Karine
Marne, Paula
Menchón, Tania
Operto, Grégory
Polo, Albina
Pradas, Sandra
Soteras, Anna
Vilanova, Marc
Vilor-Tejedor, Natàlia
-
Funding
Funding for this research was provided by:
“la Caixa” Foundation (LCF/PR/GN17/10300004)
Alzheimer's Association (TriBEKa-17-519007)
Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government (2017-SGR-892)
Ministerio de Ciencia, Innovación y Universidades (FJCI-2017-33437, IJC2018-037478-I)
Alzheimer's Association (2019-AARF-644568)
H2020 Marie Skłodowska-Curie Actions (752310)
Instituto de Salud Carlos III (PI19/00155)
Ministerio de Ciencia, Innovación y Universidades (RYC2018-026053-I, RYC-2013-13054)
Instituto de Salud Carlos III (CP II 17/00029)
swedish research council (2018-02532)
H2020 European Research Council (681712)
Alzheimer's Drug Discovery Foundation (201809-2016862, RDAPB-201809-2016615)
swedish alzheimer's foundation (AF-742881)
European union joint program for neurodegenrative diseases (JPND2019-466-236)
- License Information
-
More Information
Article History
Received: 29 September 2020
Accepted: 1 February 2021
First Online: 17 February 2021
Ethics approval and consent to participate
: The ALFA, ALFA+, and PET study protocols have been approved by the independent Ethics Committee Parc de Salut Mar Barcelona and registered at ClinicalTrials.gov (ALFA Identifier: NCT01835717; ALFA+ Identifier: NCT02485730; PET Identifier: NCT02685969). All participants signed a written informed consent before their inclusion that had also been approved by the independent Ethics Committee Parc de Salut Mar Barcelona.
: NA
: IN-G received honoraria for travel and accommodation to attend scientific meetings from Zambon, Teva, Bial, AbbVie, and Krka. MS and GK are full-time employees of Roche Diagnostics. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. JLM is currently a full- time employee of H. Lundbeck A/S and priory has served as a consultant or at advisory boards for the following for-profit companies, or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, ProMIS Neurosciences. The remaining authors report no conflicts of interest.
